NCT03317782View on ClinicalTrials.gov

NoL Index Variations Before and After a Stellate Ganglion Block

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

December 18, 2018

Study Completion Date

April 4, 2019

Conditions
Chronic Pain Syndrome
Interventions
DEVICE

NoL index

The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index \<20 indicates adequate analgesia.

Trial Locations (1)

h1t2m4

Maisonneuve Rosemont Hospital, Montreal

All Listed Sponsors
lead

Maisonneuve-Rosemont Hospital

OTHER

NCT03317782 - NoL Index Variations Before and After a Stellate Ganglion Block | Biotech Hunter | Biotech Hunter